NEW YORK, March 7, 2013 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:
The Contract Biomanufacturing Market Outlook to 2017
http://www.reportlinker.com/p01118464/The-Contract-Biomanufacturing-Market-Outlook-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical
Introduction
The volume demand for biologics active pharmaceutical ingredients (API) from 2011-2017 is set to show a 20% annual increase. Combined with a boost in biosimilars, the biologics contract manufacturing market is forecast to grow 9% per year over the same period.
Scope
• Develop a winning expansion and outsourcing strategy to grow your market share with forecasts through to 2017
• Assess the areas to target and use your findings to help increase profits with information on drivers and resistors of outsourced biomanufacturing
• Use the forecast for biologic and CMO market to adapt your strategy and ensure you're commercially successful
• With analysis on the 5 leading players you will understand what your competitors are doing and what actions you can take to stay competitive
Increasing API demand driven by biologics market growth and an increase in the number of late-stage clinical trials and approved biotech products will be the biggest drivers of the bio-CMO market.
Reasons to Buy
• What is the state of contract biomanufacturing in emerging regions?
• Who are the leading bio-CMOs and what are their strategies, strengths and weaknesses?
• What is the most attractive area of investment in the biologics market?
Table of Contents
Overview 4
Catalyst 4
–– Summary 4
Executive Summary 5
Market Overview 6
Definition 6
Segmentation 6
–– Categories of CMOs and services offered 7
References 9
Market Dynamics 10
Drivers 10
–– Growth of large molecule market 10
–– Cost savings 11
–– Risk reduction and risk sharing 11
–– Lead-time saving 11
–– Access to expertise and technology 12
–– Orphan drugs 12
–– Growth in emerging markets 13
–– Biosimilars 13
Resistors 14
–– Increasing yields and disposable technology 14
–– Overcapacity and pharma's increasing in-house capacity 14
–– Regulatory uncertainty over biosimilars 14
Market forecasts 15
–– Microbial and mammalian drug market 15
–– Microbial vs mammalian CMO market 15
–– Biosimilars 15
–– Biomanufacturing installed base 16
Contract biomanufacturing in emerging regions 17
References 17
Leading Players 19
Summary 19
Introduction 19
Boehringer Ingelheim 20
–– Overview and capabilities 20
–– Partnerships, deals, and expansion plans 20
–– SWOT analysis 21
Lonza 21
–– Overview and capabilities 21
–– Partnerships, deals, and expansion plans 22
–– SWOT analysis 22
Sandoz 23
–– Overview and capabilities 23
–– Partnerships, deals, and expansion plans 23
–– SWOT analysis 23
Fujifilm Diosynth Biotechnologies 24
–– Overview and capabilities 24
–– Partnerships, deals, and expansion plans 24
–– SWOT analysis 24
DSM 25
–– Overview and capabilities 25
–– Partnerships, deals, and expansion plans 25
–– SWOT analysis 26
References 26
Appendix 29
Methodology 29
–– Pharmaceutical market 29
–– Bio-CMO market 29
References 29
Table 1: Categories of CMOs and services offered 7
Figure 1: Biopharma value chain 7
Figure 2: Small vs large molecule pharma market ($bn), 2008–17 10
Figure 3: Number of orphan drug NMEs historically and
forecasted average in the US, 2005–16 12
Figure 4: Biopharmaceutical drug market by major product
group ($bn), 2011–17 15
Figure 5: Mammalian and microbial API CMO market ($bn),
2010–17 16
Figure 6: Comparison of leading bio-CMOs by capability 19
Companies Mentioned
First Aviation Services Inc., Hutchison 3G UK Limited
To order this report:
Biopharmaceutical Industry: The Contract Biomanufacturing Market Outlook to 2017
_________________________
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article